Related Experiment Video
Updated: Mar 10, 2026
Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer
Published on: February 9, 2024
Knockdown of ST6Gal-I increases cisplatin sensitivity in cervical cancer cells
Xiaopeng Zhang1, Chunchen Pan2, Lei Zhou3
1Department of Obstetrics and Gynecology, The First Affiliated Hospital of Anhui Medical University, Hefei, 23022, China.
Background:
Sialyltransferase I (ST6Gal-I) is an enzyme involved in tumor metastasis that processes sialic acid precursors into their mature form, enabling them to regulate gene expression. However, the effect of ST6Gal-I on the biological behavior of cancer cells remain unclear. This study was the first to demonstrate the influence of ST6Gal-I on cisplatin sensitivity in cervical cancer cells.
Methods:
Knockdown of ST6Gal-I was performed by shRNA and HeLa cells combination with cisplatin were tested.
Results:
We showed that down-regulation of ST6Gal-I promoted cell apoptosis and inhibited proliferation and invasion in cervical cancer cells. Knockdown of ST6Gal-I by RNA interference increased the sensitivity of HeLa cells to cisplatin in vitro, and reduced tumor volume and suppressed subcutaneous tumor growth in response to cisplatin treatment in a xenograft mouse model in vivo.
Conclusions:
The results provide new information that ST6Gal-I plays an important role in several biological or pathological processes including drug resistance in cervical cancer and may be a potential therapeutic target to improve the response to chemotherapy in cervical cancer patients.
Insights
Down-regulating Sialyltransferase I (ST6Gal-I) in cervical cancer cells enhances apoptosis, reduces invasion, and increases sensitivity to cisplatin chemotherapy. This enzyme is a potential therapeutic target for improving treatment outcomes.
Area of Science:
- Biochemistry
- Oncology
- Molecular Biology
Background:
- Sialyltransferase I (ST6Gal-I) is an enzyme implicated in tumor metastasis.
- ST6Gal-I processes sialic acid precursors, influencing gene expression.
- Its precise role in cancer cell behavior and drug resistance was unclear.
Purpose of the Study:
- To investigate the influence of ST6Gal-I on the biological behavior of cervical cancer cells.
- To determine the effect of ST6Gal-I on cisplatin sensitivity in cervical cancer.
Main Methods:
- ST6Gal-I was downregulated using short hairpin RNA (shRNA).
- HeLa cervical cancer cells were treated with cisplatin.
- Effects were assessed in vitro and in a xenograft mouse model.
Main Results:
- Downregulation of ST6Gal-I promoted apoptosis and inhibited proliferation and invasion.
- ST6Gal-I knockdown increased cisplatin sensitivity in HeLa cells.
- In vivo, reduced ST6Gal-I suppressed tumor growth in response to cisplatin.
Conclusions:
- ST6Gal-I plays a significant role in cervical cancer progression and drug resistance.
- Targeting ST6Gal-I may enhance chemotherapy response in cervical cancer patients.
- ST6Gal-I is a potential therapeutic target for improving chemotherapy efficacy.
